The Potential of Candesartan to Retard the Progression of Aortic Stenosis
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The present study defines a blinded, randomized, placebo-controlled, prospective study, the
aim of which is to determine the influence of effective treatment with Type 1 angiotensin II
(Ang II) receptor (AT-1R) antagonist, using candesartan (target dose 16 mg) on stenotic
aortic valves. The investigators will specifically quantify whether candesartan attenuates
the key pathogenic mechanisms of aortic valve stenosis, namely inflammation, fibrosis,
elastin degradation, calcification, and neovascularization.